rinvoq 15 mg/1 tableta tableta s produženim oslobađanjem
abbvie d.o.o. - upadacitinib - tableta s produženim oslobađanjem - 15 mg/1 tableta - 1 tableta sa produženim oslobađanjem sadrži: 15 mg upadacitiniba u obliku upadacitinib hemihidrata
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
rinvoq 15mg tableta sa produženim oslobađanjem
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - upadacitinib - tableta sa produženim oslobađanjem - 15mg
cibinqo
pfizer europe ma eeig - abrocitinib - dermatitis, atopic - ostali dermatološki pripravci - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
cibinqo 50mg film tableta
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - abrocitinib - film tableta - 50mg
cibinqo 100mg film tableta
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - abrocitinib - film tableta - 100mg
cibinqo 200mg film tableta
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - abrocitinib - film tableta - 200mg
paxlovid 150mg + 100mg film tableta
"evropa lek pharma" doo podgorica - nirmatrelvir, ritonavir - film tableta - 150mg + 100mg
xeljanz 10mg film tableta
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - tofacitinib - film tableta - 10mg
xeljanz 5mg film tableta
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - tofacitinib - film tableta - 5mg